525MO Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775

N Colombo,D Lorusso,G Barresi,K Ushijima,J Huang,Eva María Guerra Alía ,I.L Ray-Coquard,S.E Baron-Hay,K Yonemori,B.J Monk,H Mackay,U.A Sanli,D.S Miller,V Makker,Y.M Kim,J Mckenzie,R.G Moore,R Shapira-Frommer,A.D Santin,A Casado Herráez

doi:10.1016/j.annonc.2022.07.653

525MO Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775

N Colombo, D Lorusso + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.653

Copy DOI

Journal: Annals of Oncology	Publication Date: Sep 1, 2022
Citations: 2	License type: publisher-specific-oa

#Treatment Of Physician’s Choice #Lenvatinib + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The primary endpoint hypotheses for the phase 3 Study 309/KEYNOTE-775 were formally tested at interim analysis 1; LEN + pembro demonstrated statistically significant improvements in PFS and OS vs TPC in pts with aEC. ORR was higher with LEN + pembro vs TPC. We report updated analyses of this study.

Full Text